<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01594892</url>
  </required_header>
  <id_info>
    <org_study_id>DOSIS</org_study_id>
    <nct_id>NCT01594892</nct_id>
  </id_info>
  <brief_title>Fractionated Radiosurgery for Painful Spinal Metastases</brief_title>
  <acronym>DOSIS</acronym>
  <official_title>Dose-intensified Image-Guided Fractionated Radiosurgery for Spinal Metastases (DOSIS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wuerzburg University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Royal Marsden NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Wuerzburg University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is the study hypothesis that hypo-fractionated image-guided radiosurgery significantly
      improves pain relief compared to historic data of conventionally fractionated radiotherapy.
      Primary endpoint is pain response 3 months after radiosurgery, which is defined as pain
      reduction of ≥2 points at the treated vertebral site on the 0 to 10 Visual Analogue Scale. 60
      patients will be included into this II trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The current study will investigate efficacy and safety of radiosurgery for painful vertebral
      metastases and three characteristics will distinguish this study.

        1. A prognostic score for overall survival will be used for selection of patients with
           longer life expectancy to allow for analysis of long-term efficacy and safety.

        2. Fractionated radiosurgery will be performed with the number of treatment fractions
           adjusted to either good (10 fractions) or intermediate (5 fractions) life expectancy.
           Fractionation will allow inclusion of tumors immediately abutting the spinal cord due to
           higher biological effective doses at the tumor - spinal cord interface compared to
           single fraction treatment.

        3. Dose intensification will be performed in the involved parts of the vertebrae only,
           while uninvolved parts are treated with conventional doses using the simultaneous
           integrated boost concept.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">July 2017</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Evaluation of the single intervention - dose-intensified SBRT</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients, in whom pain is decreased in response to treatment</measure>
    <time_frame>Change in pain from baseline to 3 months post-treatment</time_frame>
    <description>Decrease in pain by ≥2 points at the treated vertebral site on the 0 (no pain) to 10 (the severest pain) Visual Analogue Scale without analgesic increase</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Local tumor control</measure>
    <time_frame>2 years</time_frame>
    <description>At the treated vertebral levels assessed with MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local tumor control</measure>
    <time_frame>2 years</time_frame>
    <description>At the treated vertebral levels assessed with CT imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years</time_frame>
    <description>Death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-assessed 5 dimensions of patient's quality-of-life</measure>
    <time_frame>Changes in quality of life from baseline to 3 months post-treatment</time_frame>
    <description>Measured with the 5‐level (no problems, slight problems, moderate problems, severe problems, and extreme problems) EuroQol 5‐Dimension Questionnaire (EQ-5D) questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-assessed overall health status</measure>
    <time_frame>Changes in quality of life from baseline to 3 months post-treatment</time_frame>
    <description>Measured with the EuroQol Visual Analog Scale from 0 (&quot;the worst health you can imagine&quot;) to 100 (the best health you can imagine&quot;)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients developing acute toxicity</measure>
    <time_frame>Changes from baseline up to 6 weeks post-treatment</time_frame>
    <description>Measured with NCI CTCAE v 4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients developing late toxicity</measure>
    <time_frame>Changes from &gt;6weeks up to 2 years post-treatment</time_frame>
    <description>Measured with NCI CTCAE v 4.0</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Neoplasm Metastasis</condition>
  <condition>Neoplastic Processes</condition>
  <condition>Neoplasm Recurrence, Local</condition>
  <condition>Neoplasm, Residual</condition>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Dose intensified SBRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Depending on the modified Mizumoto Score (0-4 points or 5-9 points) patients will be treated with 10 fractions of 4.85Gy in involved parts of the vertebra and 3Gy in not-involved parts using a simultaneous integrated boost or with 5 fractions of 7Gy in involved parts of the vertebra and 4Gy in not-involved parts using a simultaneous integrated boost, respectively.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiosurgery</intervention_name>
    <description>Fractionated radiosurgery using intensity-modulated treatment planning and volumetric image-guided treatment delivery</description>
    <arm_group_label>Dose intensified SBRT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Established histological diagnosis of a malignant tumour (primary or metastatic)

          2. Vertebral metastasis confirmed via biopsy or radiology

          3. Pain in the involved spinal region or free of pain under pain medication

          4. Fully consenting patients, &gt;18 years old

          5. Karnofsky Performance Index ≥60%

          6. Good or intermediate life expectancy according to the modified prognostic Mizumoto
             Score (score ≤ 9)

          7. Patient must be able to tolerate fixation systems and 30 minutes treatment time

          8. Discussed in interdisciplinary tumour board

          9. The following types of spinal tumours are eligible:

               -  Recurrent / residual tumours after surgery

               -  Tumours in medically inoperable patients or patients deemed inoperable due to
                  limited life expectancy / tumour load

               -  Lesions associated with significant surgical risk

        Exclusion Criteria:

          1. Short life expectancy according to the modified Mizumoto Sore

          2. &quot;Radiosensitive&quot; histologies (i.e. lymphoma, SCLC, multiple myeloma)

          3. Non-ambulatory status

          4. Progressive neurological symptoms/deficit

          5. &gt; 3 involved vertebral levels

          6. &gt; 2 treatment sites

          7. Spine instability

          8. Previous radiotherapy at the involved levels
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthias Guckenberger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Radiation Oncology, University of Wuerzburg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Leopoldina Schweinfurt</name>
      <address>
        <city>Schweinfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Radiation Oncology, University of Wuerzburg</name>
      <address>
        <city>Wuerzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Netherlands Cancer Institute</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Zurich</name>
      <address>
        <city>Zurich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden Hospital NHS Foundation Trust</name>
      <address>
        <city>Sutton</city>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Guckenberger M, Hawkins M, Flentje M, Sweeney RA. Fractionated radiosurgery for painful spinal metastases: DOSIS - a phase II trial. BMC Cancer. 2012 Nov 19;12:530. doi: 10.1186/1471-2407-12-530.</citation>
    <PMID>23164174</PMID>
  </reference>
  <results_reference>
    <citation>Guckenberger M, Sweeney RA, Hawkins M, Belderbos J, Andratschke N, Ahmed M, Madani I, Mantel F, Steigerwald S, Flentje M. Dose-intensified hypofractionated stereotactic body radiation therapy for painful spinal metastases: Results of a phase 2 study. Cancer. 2018 May 1;124(9):2001-2009. doi: 10.1002/cncr.31294. Epub 2018 Mar 2.</citation>
    <PMID>29499073</PMID>
  </results_reference>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>May 7, 2012</study_first_submitted>
  <study_first_submitted_qc>May 7, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 9, 2012</study_first_posted>
  <last_update_submitted>September 2, 2019</last_update_submitted>
  <last_update_submitted_qc>September 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Spinal metastases</keyword>
  <keyword>Vertebral metastases</keyword>
  <keyword>Radiosurgery</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>Stereotactic body radiotherapy</keyword>
  <keyword>Pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Neoplasm Recurrence, Local</mesh_term>
    <mesh_term>Neoplastic Processes</mesh_term>
    <mesh_term>Neoplasm, Residual</mesh_term>
    <mesh_term>Recurrence</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

